May 1, 2014 — Volcano Corp. announced the commencement of its limited market release of its U.S. Food and Drug Administration (FDA) cleared and CE marked technology SyncVision, with cases being performed in the United States and Europe. SyncVision is currently installed in multiple limited market release sites throughout the United States and Europe.
Volcano's SyncVision technology system is an online image processing workstation for coronary catheterizations that allows the physician to navigate simultaneously on an angiogram and on an intravascular ultrasound (IVUS) image in a single correlated view using co-registration of the Eagle Eye Platinum catheter with X-ray angiography. SyncVision is designed to bring the detailed vessel, lumen and wall structure from angiography and the spatial localization of Volcano's intravascular ultrasound images within the coronary tree together in a co-registered view to facilitate more informed treatment decisions and more efficient, enhanced workflow performance.
"SyncVision is an important advancement in clinical IVUS imaging. It allows us to correlate significant IVUS findings with the corresponding spots on the angiogram. This addresses a challenging aspect of current practice in that it can be difficult to identify the precise spot needing treatment in translating the IVUS findings to the angiogram," commented Steven Goldberg, M.D., director, cardiac catheterization laboratory and clinical associate professor of medicine at University of Washington Medical Center. "It also allows for simple and precise length measurements to help inform stent selection. Co-registration of different imaging modalities is currently the wave in interventional cardiology, and I think this is one of the most useful and user friendly co-registration formats I have seen. I believe that this truly represents the next generation in IVUS imaging."
"The co-registration with angiography makes of IVUS an entirely new instrument. As a regular IVUS user, I was impressed to see how it helps in making decisions based on intracoronary imaging," commented Javier Escaned, M.D., consultant interventional cardiologist, Hospital Clinico San Carlos, Madrid, Spain. "In addition, the angiographic tools incorporated in SyncVision are extremely helpful during coronary interventions. Image stabilization and digital enhancement based not only on cine but also on images under fluoroscopy is a great complement of IVUS in performing accurate stent optimization without geometric mismatch. My impression is that with this system we move into an entirely new era of integration of IVUS and angiography in clinical practice."
"We are looking forward to sharing the SyncVision technology with a global audience next month at the EuroPCR meeting in Paris," said Joe Burnett, executive vice president. "We will showcase the technology with working systems at our booth and in the training village, as well as with expert panel discussions and live case presentations."
SyncVision is expected to be in full market release later in 2014.
For more information: www.volcanocorp.com
November 14, 2025 
